Clinical Trials
6
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:4
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Phase 2
2 (33.3%)Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Phase 2
Recruiting
- Conditions
- Advanced Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 75
- Registration Number
- NCT06173362
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Phase 1
Recruiting
- Conditions
- Recurrent Non-Muscle Invasive Bladder CarcinomaStage 0is Bladder Cancer AJCC v8Stage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8
- Interventions
- Drug: PLZ4-coated paclitaxel loaded micelles (PPM)
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 12
- Registration Number
- NCT06173349
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
Phase 1
Recruiting
- Conditions
- Refractory Urothelial CarcinomaLocally Advanced Urothelial CarcinomaAdvanced Urothelial CarcinomaMetastatic Urothelial Carcinoma
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 12
- Registration Number
- NCT04856189
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Stage IV Prostate CancerRecurrent Prostate CarcinomaMetastatic Prostate Carcinoma
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 6
- Registration Number
- NCT03123978
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 38
- Registration Number
- NCT02935205
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Prev
- 1
- 2
- Next
News
No news found